Eli Lilly and Co
XHAM:LLY
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
541
952.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
1T USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
519.1B USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
380.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
274.5B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
277.1B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
182.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
158.6B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
146.2B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
109.7B USD |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
77.7B USD |
Loading...
|
Market Distribution
| Min | -4 087 900% |
| 30th Percentile | -5.1% |
| Median | 6% |
| 70th Percentile | 14.8% |
| Max | 1 032 600% |
Other Profitability Ratios
Eli Lilly and Co
Glance View
Eli Lilly and Co. has long been a stalwart in the pharmaceutical industry, sculpting its trajectory through innovation and strategic acumen. Founded in 1876 by Colonel Eli Lilly, the company has grown from a small chemical firm into a global powerhouse in developing life-changing medications. Its headquarters in Indianapolis, Indiana, serve as a hub of research and development, where groundbreaking scientific exploration meets business strategy. Eli Lilly thrives on its core pillars of innovation in oncology, immunology, and diabetes care, relying on a deep commitment to scientific discovery and patient care. This emphasis allows it to consistently bring cutting-edge treatments to market, boosting its reputation as a leader in pharmaceuticals and maintaining a strong pipeline of drugs that drive future growth. The company's business model is principally built around creating proprietary medications that command premium pricing due to their uniqueness and effectiveness. This model sustains Eli Lilly's revenue through a dual approach: serving mature markets with established products and fueling growth with new launches. Patents on flagship drugs protect these revenue streams, allowing the company to invest substantially in research and development, which in recent years prioritizes personalized medicine and biotechnology. Collaborations with academic institutions and other corporations have also been pivotal, accelerating drug development and expanding Eli Lilly's reach across therapeutic areas. Overall, its ability to navigate regulatory frameworks and maintain robust sales and marketing strategies ensures its medications reach patients globally, securing its financial health and influence within the healthcare landscape.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Eli Lilly and Co is 44.4%, which is above its 3-year median of 34%.
Over the last 3 years, Eli Lilly and Co’s Operating Margin has increased from 29.3% to 44.4%. During this period, it reached a low of 26.4% on Mar 31, 2023 and a high of 44.4% on Sep 30, 2025.